This company has been acquired
GTHX Stock Overview
A commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
G1 Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.15 |
| 52 Week High | US$7.19 |
| 52 Week Low | US$1.08 |
| Beta | 1.68 |
| 1 Month Change | 0.85% |
| 3 Month Change | 182.61% |
| 1 Year Change | 433.58% |
| 3 Year Change | -52.55% |
| 5 Year Change | -78.80% |
| Change since IPO | -52.33% |
Recent News & Updates
Recent updates
There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise
Jul 26
G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty
Jun 24Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why
Jun 07Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
May 28G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 04Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape
Mar 22Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge
Feb 27Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?
Feb 06G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry
Jan 04Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues
Jun 08New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)
May 08The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts
Nov 04G1 Therapeutics: Catalysts Stacking
Oct 20G1 Therapeutics: Building A Franchise
Sep 29Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)
Aug 04G1 Therapeutics Q2 2022 Earnings Preview
Aug 02G1 Therapeutics: Take Advantage Of The November Data
Jul 22Shareholder Returns
| GTHX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.3% | -1.9% | -2.8% |
| 1Y | 433.6% | -5.7% | 24.1% |
Return vs Industry: GTHX exceeded the US Biotechs industry which returned 20.4% over the past year.
Return vs Market: GTHX exceeded the US Market which returned 25.3% over the past year.
Price Volatility
| GTHX volatility | |
|---|---|
| GTHX Average Weekly Movement | 19.9% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GTHX's share price has been volatile over the past 3 months.
Volatility Over Time: GTHX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 100 | Jack Bailey | www.g1therapeutics.com |
G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer.
G1 Therapeutics, Inc. Fundamentals Summary
| GTHX fundamental statistics | |
|---|---|
| Market cap | US$378.17m |
| Earnings (TTM) | -US$44.77m |
| Revenue (TTM) | US$58.20m |
6.5x
P/S Ratio-8.4x
P/E RatioIs GTHX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GTHX income statement (TTM) | |
|---|---|
| Revenue | US$58.20m |
| Cost of Revenue | US$6.14m |
| Gross Profit | US$52.05m |
| Other Expenses | US$96.82m |
| Earnings | -US$44.77m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 89.44% |
| Net Profit Margin | -76.93% |
| Debt/Equity Ratio | 180.2% |
How did GTHX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/18 07:44 |
| End of Day Share Price | 2024/09/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
G1 Therapeutics, Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harshita Polishetty | B. Riley Securities, Inc. |
| Dane Leone | BTIG |
| Charles Butler | D. Boral Capital LLC. |